Efgartigimod alfa is administered as an intravenous (IV) infusion. It is important that the infusion is given under the supervision of a healthcare professional. The infusion is usually delivered in a medical setting such as a hospital or clinic. Here are the general instructions for administration:

• Preparation: The medication is prepared by a healthcare provider and diluted for intravenous use.
  
  
• Administration: The infusion is given over a period of time (usually 1 to 2 hours) depending on the patient’s response and tolerance.
  
  
• Monitoring: Patients receiving Efgartigimod alfa should be monitored during and after the infusion for signs of an infusion reaction or any adverse effects, such as fever, chills, or headaches.
  
  

It is essential to follow all instructions from the healthcare provider to ensure the medication is administered correctly and safely.

Efgartigimod alfa works by targeting and blocking the neonatal Fc receptor (FcRn), a protein that regulates the amount of certain antibodies in the bloodstream. The FcRn is involved in the recycling of immunoglobulin G (IgG) antibodies, which are responsible for various immune responses, including the formation of autoantibodies that attack normal body tissues in autoimmune diseases.

In Generalized Myasthenia Gravis (gMG), the immune system produces autoantibodies against the acetylcholine receptors (AChRs) or other components of the neuromuscular junction, leading to impaired communication between nerves and muscles, which causes muscle weakness.

By inhibiting FcRn, Efgartigimod alfa accelerates the degradation of these harmful autoantibodies, thus reducing their concentration in the blood. This action helps prevent further damage to the neuromuscular junction, improving muscle strength and function in patients with gMG.

Since Efgartigimod alfa lowers the levels of harmful antibodies rather than suppressing the overall immune system, it presents a more targeted approach to managing autoimmune diseases like gMG, with a potentially lower risk of systemic immune suppression and infections compared to other immunosuppressive therapies.

As with any medication, Efgartigimod alfa can cause side effects, although not all patients will experience them. Some of the common and serious side effects include:

Common Side Effects:

• Headache: Some patients may experience headaches, especially after the infusion.
  
  
• Fatigue: Tiredness and fatigue are common side effects and may occur during or after treatment.
  
  
• Upper Respiratory Tract Infections: Patients may experience symptoms similar to a cold or respiratory infection, including sore throat and congestion.
  
  

Serious Side Effects:

• Infusion-Related Reactions: Some patients may experience reactions during the infusion, such as fever, chills, dizziness, or difficulty breathing. These reactions are typically temporary and can be managed by slowing or stopping the infusion.
  
  
• Infections: Since Efgartigimod alfa reduces levels of specific antibodies, patients may be at an increased risk of infections, especially during the early stages of treatment.
  
  
• Hypersensitivity Reactions: Although rare, some individuals may develop allergic reactions to Efgartigimod alfa, including rash, swelling, or difficulty breathing.
  
  

If any of these side effects occur, contact a healthcare provider immediately.

There are several important warnings and precautions to consider when using Efgartigimod alfa:

• Infection Risk: Since Efgartigimod alfa reduces autoantibodies, patients may have an increased risk of infections. Patients should be monitored for signs of infection, especially during the early phases of treatment.
  
  
• Infusion Reactions: Some patients may experience reactions during the infusion, so it is important to have the medication administered under the supervision of healthcare professionals who can manage these reactions.
  
  
• Pregnancy and Breastfeeding: The safety of Efgartigimod alfa during pregnancy and breastfeeding has not been fully established. Patients should discuss their options with their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding.
  
  

Efgartigimod alfa is a monoclonal antibody, so it is less likely to interact with other medications in the same way as oral drugs. However, some potential interactions may still exist, particularly with medications that affect the immune system:

• Immunosuppressants: Since Efgartigimod alfa affects the immune system by reducing the levels of specific autoantibodies, using it with other immunosuppressants, such as corticosteroids, methotrexate, or azathioprine, may increase the risk of infections or other immune-related complications.
  
  
• Vaccines: As Efgartigimod alfa can impact immune function, it is important to discuss vaccination plans with a healthcare provider before starting treatment. Some vaccines may not be as effective during treatment, or the patient may need to adjust their vaccine schedule.
  
  

As with any medication, it is important to inform your healthcare provider of all the medications you are currently taking, including over-the-counter drugs and supplements, to avoid potential interactions.

The usual dosing regimen for Efgartigimod alfa involves:

• Loading Dose: 10 mg/kg intravenously once a week for 4 weeks.
  
  
• Maintenance Dose: After the initial 4 weeks, the maintenance dose is 10 mg/kg every 4 weeks.
  
  

Dosage adjustments may be necessary depending on patient response and tolerance.

Efgartigimod alfa is a prescription-only medication and should only be administered under the supervision of a healthcare provider. A doctor will evaluate whether Efgartigimod alfa is suitable based on the patient’s medical history, the severity of their condition, and any other ongoing treatments.

1. What is Efgartigimod Alfa?
   It’s a medication designed to reduce harmful antibodies in certain autoimmune conditions.

2. What conditions does Efgartigimod Alfa treat?
   Primarily generalized myasthenia gravis (gMG) in adults who are AChR antibody-positive.

3. How does Efgartigimod Alfa work?
   It blocks the neonatal Fc receptor (FcRn), leading to faster breakdown of IgG antibodies.

4. Is Efgartigimod Alfa an immunosuppressant?
   It is not a traditional immunosuppressant but modulates antibody levels selectively.

5. How is Efgartigimod Alfa given?
   It’s administered by intravenous infusion over about one hour.

6. How often is Efgartigimod Alfa used?
   Typically once weekly for four weeks per treatment cycle.

7. What are the common side effects of Efgartigimod Alfa?
   Headache, upper respiratory infections, and infusion-related reactions.

8. Is Efgartigimod Alfa safe for long-term use?
   Clinical trials suggest good safety, but ongoing monitoring is recommended.

9. Can Efgartigimod Alfa be used with other myasthenia gravis treatments?
   Yes, but it should be supervised by a healthcare provider to avoid interactions.

10. Does Efgartigimod Alfa affect vaccines?
    It may reduce vaccine effectiveness since it lowers antibody levels.

11. Can Efgartigimod Alfa be used during pregnancy?
    Safety is not fully established—use only if the benefit outweighs risks.

12. Is Efgartigimod Alfa used in children?
    Currently, it is only approved for adults.

13. What monitoring is required during Efgartigimod Alfa treatment?
    Doctors may check infection signs, antibody levels, and overall health.

14. How quickly does Efgartigimod Alfa work?
    Some patients notice improvement within weeks after starting treatment.

15. Is Efgartigimod Alfa a cure for myasthenia gravis?
    No—it controls symptoms but does not cure the disease.

16. Does Efgartigimod Alfa suppress the entire immune system?
    No, it mainly reduces harmful IgG antibodies while leaving other immune defenses intact.

17. How is Efgartigimod Alfa stored?
    In a refrigerator, protected from light, until prepared for infusion.

18. Can Efgartigimod Alfa cause allergic reactions?
    Yes—though rare, infusion reactions and hypersensitivity may occur.

19. Is Efgartigimod Alfa widely available?
    Yes, but mainly through specialty pharmacies and infusion centers.

20. Who should not use Efgartigimod Alfa?
    People with severe hypersensitivity to the drug or its ingredients.